Douglas Rissing
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for the company’s lead asset, REC-4881.
Analyst Priyanka Grover argued that REC-4881, for which